Amerigen loses patent case against UCB at Federal Circuit
US-based Amerigen Pharmaceuticals has lost in its bid to prove that claims in a patent owned by biopharmaceutical company UCB were covered by a prior invention.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
7 February 2019 In a victory for Mayo Collaborative Services, a US Court has ruled that four claims in a patent, of which Athena Diagnostics is the exclusive licensee, are invalid.
24 May 2018 Pharmaceutical company UCB has emerged victorious in a case against major generic drug companies after its patent win was affirmed on appeal.
7 February 2019 In a victory for Mayo Collaborative Services, a US Court has ruled that four claims in a patent, of which Athena Diagnostics is the exclusive licensee, are invalid.
24 May 2018 Pharmaceutical company UCB has emerged victorious in a case against major generic drug companies after its patent win was affirmed on appeal.
7 February 2019 In a victory for Mayo Collaborative Services, a US Court has ruled that four claims in a patent, of which Athena Diagnostics is the exclusive licensee, are invalid.
24 May 2018 Pharmaceutical company UCB has emerged victorious in a case against major generic drug companies after its patent win was affirmed on appeal.